NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.480
-0.050 (-3.27%)
Jul 24, 2026, 4:00 PM EDT - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,155,856
Market Cap
33.71M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PDS Biotechnology | 21 |
| Veru Inc. | 20 |
| Lantern Pharma | 16 |
| BriaCell Therapeutics | 16 |
| Serina Therapeutics | 16 |
| CervoMed | 15 |
| Nutriband | 13 |
| Genenta Science | 9 |
NNVC News
- 2 days ago - NanoViricides prices $3.8M registered direct offering - TheFly
- 2 days ago - NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - Accesswire
- 4 days ago - NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial - TheFly
- 13 days ago - NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial - TheFly
- 13 days ago - As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo - Accesswire
- 18 days ago - Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - Accesswire
- 20 days ago - NanoViricides initiated with an Outperform at Noble Capital - TheFly
- 20 days ago - NanoViricides advances towards Phase II clinical trial of NV-387 - TheFly